# Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

> **NCT02969044** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-06651600

## Key facts

- **NCT ID:** NCT02969044
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-20
- **Primary completion:** 2017-12-12
- **Final completion:** 2017-12-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02969044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02969044, "Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02969044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*